← Leaderboards
Owen A O''connor
Columbia University Health Sciences
$1,850,778
Attributed
$3,063,062
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $808.7K · FY2008–25$1M$750K$500K$250K$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
FDA$2,772,901 · 2
NIH$290,161 · 1
By mechanism
R01$2,772,901 · 2
P30$290,161 · 1
Top collaborators
- Enrica Marchi3 shared
Most similar at Columbia University Health Sciences
Same institution · by research overlap
- Adolfo A. Ferrando$15,202,284
- Shan Zha$19,854,363
- Laura Pasqualucci$5,549,983
- Anil K Rustgi$51,275,906
- Uttiya Basu$20,146,070
Others in their field
Top investigators on “Lymphoid Tissue”
- Lawrence Corey · Fred Hutchinson Cancer Center$215,765,815
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$103,177,619
- Constance Ann Benson · University Of California, San Diego$65,790,143
- Steven G. Self · Fred Hutchinson Cancer Research Center$43,947,468
- Troy D Randall · University Of Alabama At Birmingham$32,008,558
- Steven Grant Deeks · University Of California Los Angeles$30,309,119
Research focus
Lymphoid TissueMalignant NeoplasmsBudgetsB-Cell Nonhodgkins LymphomaMalignant Lymphoid NeoplasmLymphomaClinical TrialsCollegeDevelopment Of Lymphoid MalignancyCancer CellDirect CostsFundingGenesGeneticGrantGrowthImmature LymphocyteLesionLeukemia, Lymphocytic, AcuteLeukemia/LymphomaDifferentiation And GrowthLymphoidLymphoid CellMature B-Lymphocyte
Grant awards (12)
A Randomized, Phase IIB, Multicenter, Trial of Oral Azacytidine Plus Romidepsin versus Investigator's Choice in Patients with Relapse or Refractory Periperal T-cell lymphoma (PTCL).$808,684
R01 · FY2025 · FD · contact PI
A Randomized, Phase IIB, Multicenter, Trial of Oral Azacytidine Plus Romidepsin versus Investigator's Choice in Patients with Relapse or Refractory Periperal T-cell lymphoma (PTCL).$808,153
R01 · FY2022 · FD · contact PI
A Randomized, Phase IIB, Multicenter, Trial of Oral Azacytidine Plus Romidepsin versus Investigator's Choice in Patients with Relapse or Refractory Periperal T-cell lymphoma (PTCL).$807,732
R01 · FY2020 · FD · contact PI
LYMPHOID DVLP AND MALIGNANCIES (LDM)$136,392
P30 · FY2013 · CA · contact PI
LYMPHOID DVLP AND MALIGNANCIES (LDM)$30,167
P30 · FY2012 · CA · contact PI
LYMPHOID DVLP AND MALIGNANCIES (LDM)$33,683
P30 · FY2011 · CA · contact PI
LYMPHOID DVLP AND MALIGNANCIES (LDM)$34,400
P30 · FY2010 · CA · contact PI
LYMPHOID DVLP AND MALIGNANCIES (LDM)$34,254
P30 · FY2009 · CA · contact PI
LYMPHOID DVLP AND MALIGNANCIES (LDM)$417
P30 · FY2009 · CA · contact PI
A MULTICENTER PHASE 2 TRIAL OF PRALTREXATE W/RELAPSED$213,146
R01 · FY2008 · FD · contact PI
A MULTICENTER PHASE 2 TRIAL OF PRALTREXATE W/RELAPSED$135,186
R01 · FY2008 · FD · contact PI
LYMPHOID DVLP AND MALIGNANCIES (LDM)$20,848
P30 · FY2008 · CA · contact PI